LORA HORTON: Open Payments
NPI 1962006585 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,237 in 177 payments from 23 companies in 2025. Trend: 2023 $1,809 · 2024 $2,352 · 2025 $3,237
Food & beverage: $3,237
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 59 | $853 |
| Janssen Biotech, Inc. | 18 | $349 |
| PFIZER INC. | 16 | $313 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $255 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $237 |
| Gilead Sciences, Inc. | 10 | $192 |
| Madrigal Pharmaceuticals | 7 | $178 |
| Regeneron Healthcare Solutions, Inc. | 6 | $149 |
| GENZYME CORPORATION | 6 | $121 |
| Celltrion USA Inc. | 4 | $99 |
Products named: RINVOQ, TREMFYA, DUPIXENT, ENTYVIO, XIFAXAN, SKYRIZI, REZDIFFRA, VELSIPITY.
Industry payments across OK — which companies pay providers there.
